Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia

OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychiatric services (Washington, D.C.) D.C.), 2001-11, Vol.52 (11), p.1510-1514
Hauptverfasser: Citrome, Leslie, Volavka, Jan, Czobor, Pal, Sheitman, Brian, Lindenmayer, Jean-Pierre, McEvoy, Joseph, Cooper, Thomas B., Chakos, Miranda, Lieberman, Jeffrey A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1514
container_issue 11
container_start_page 1510
container_title Psychiatric services (Washington, D.C.)
container_volume 52
creator Citrome, Leslie
Volavka, Jan
Czobor, Pal
Sheitman, Brian
Lindenmayer, Jean-Pierre
McEvoy, Joseph
Cooper, Thomas B.
Chakos, Miranda
Lieberman, Jeffrey A.
description OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial. The trial was divided into two periods: eight weeks during which the dosage was escalated and then fixed, and six weeks during which variable dosages were used. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the items that reflect positive symptoms of schizophrenia (delusions, suspiciousness or feelings of persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinations) and the sedation item of the Nurses Observation Scale for Inpatient Evaluation (NOSIE). RESULTS: Patients differed in their treatment response as measured by the hostility item of the PANSS. The scores of patients taking clozapine indicated significantly greater improvement than those of patients taking haloperidol or risperidone. The effect on hostility appeared to be independent of the antipsychotic effect of clozapine on other PANSS items that reflect delusional thinking, a formal thought disorder, or hallucinations and independent of sedation as measured by the NOSIE. Neither risperidone nor olanzapine showed superiority to haloperidol. CONCLUSION: Clozapine has a relative advantage over other antipsychotics as a specific antihostility agent.
doi_str_mv 10.1176/appi.ps.52.11.1510
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72240211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72240211</sourcerecordid><originalsourceid>FETCH-LOGICAL-a369t-ef103f56f9703d5166c7d262aad117ee1f1592f4cf0436cdec4a410f8e50f4d63</originalsourceid><addsrcrecordid>eNp9kM1OGzEUha2qqNC0L8Ci8qasmODr8U-yRBGQSkhB0KpLy_XYxGjGdu3JAp4eT5OKHSvfY333XJ2D0CmQOYAUFzolP09lzmnVc-BAPqAT4Fw2S0nIxzoTyRsqW3KMPpfyRAgBCeITOgYQCybZ4gQNV85ZMxYcHV718UUnH-w53vQ6_J_vfUk2-y5OQocOr3Uf9z89jgGvYxl978dnfDnE8Ijv9OhtqJa__bjFD2brX2LaZhu8_oKOnO6L_Xp4Z-jX9dXP1bq53dz8WF3eNroVy7GxDkjruHA1R9txEMLIjgqqdVeDWwsO-JI6ZhxhrTCdNUwzIG5hOXGsE-0Mne19U45_d7aMavDF2L6msnFXlKSUEQpQQboHTY6lZOtUyn7Q-VkBUVPJaipZpaI4rVpNJdelbwf33Z_Bdm8rh1Yr8P0A6GJ077IOxpc3jpElE3wyuthz_448xV0OtZX3Tr8CQi-XJg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72240211</pqid></control><display><type>article</type><title>Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia</title><source>MEDLINE</source><source>American Psychiatric Publishing Journals (1997-Present)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><creator>Citrome, Leslie ; Volavka, Jan ; Czobor, Pal ; Sheitman, Brian ; Lindenmayer, Jean-Pierre ; McEvoy, Joseph ; Cooper, Thomas B. ; Chakos, Miranda ; Lieberman, Jeffrey A.</creator><creatorcontrib>Citrome, Leslie ; Volavka, Jan ; Czobor, Pal ; Sheitman, Brian ; Lindenmayer, Jean-Pierre ; McEvoy, Joseph ; Cooper, Thomas B. ; Chakos, Miranda ; Lieberman, Jeffrey A.</creatorcontrib><description>OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial. The trial was divided into two periods: eight weeks during which the dosage was escalated and then fixed, and six weeks during which variable dosages were used. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the items that reflect positive symptoms of schizophrenia (delusions, suspiciousness or feelings of persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinations) and the sedation item of the Nurses Observation Scale for Inpatient Evaluation (NOSIE). RESULTS: Patients differed in their treatment response as measured by the hostility item of the PANSS. The scores of patients taking clozapine indicated significantly greater improvement than those of patients taking haloperidol or risperidone. The effect on hostility appeared to be independent of the antipsychotic effect of clozapine on other PANSS items that reflect delusional thinking, a formal thought disorder, or hallucinations and independent of sedation as measured by the NOSIE. Neither risperidone nor olanzapine showed superiority to haloperidol. CONCLUSION: Clozapine has a relative advantage over other antipsychotics as a specific antihostility agent.</description><identifier>ISSN: 1075-2730</identifier><identifier>EISSN: 1557-9700</identifier><identifier>DOI: 10.1176/appi.ps.52.11.1510</identifier><identifier>PMID: 11684748</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adult ; Adult and adolescent clinical studies ; Antipsychotic Agents - pharmacology ; Antipsychotic Agents - therapeutic use ; Benzodiazepines ; Biological and medical sciences ; Clozapine - pharmacology ; Clozapine - therapeutic use ; Dose-Response Relationship, Drug ; Double-Blind Method ; Emotions - drug effects ; Female ; Haloperidol - pharmacology ; Haloperidol - therapeutic use ; Hostility ; Humans ; Linear Models ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Pirenzepine - analogs &amp; derivatives ; Pirenzepine - pharmacology ; Pirenzepine - therapeutic use ; Prospective Studies ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Psychotic Disorders - drug therapy ; Psychotic Disorders - psychology ; Risperidone - pharmacology ; Risperidone - therapeutic use ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenic Psychology ; Statistics, Nonparametric ; Survival Analysis</subject><ispartof>Psychiatric services (Washington, D.C.), 2001-11, Vol.52 (11), p.1510-1514</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a369t-ef103f56f9703d5166c7d262aad117ee1f1592f4cf0436cdec4a410f8e50f4d63</citedby><cites>FETCH-LOGICAL-a369t-ef103f56f9703d5166c7d262aad117ee1f1592f4cf0436cdec4a410f8e50f4d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ps.52.11.1510$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ps.52.11.1510$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>315,782,786,2859,2863,21635,21636,21637,21638,27933,27934,77801,77802,77804,77809</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14094650$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11684748$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Citrome, Leslie</creatorcontrib><creatorcontrib>Volavka, Jan</creatorcontrib><creatorcontrib>Czobor, Pal</creatorcontrib><creatorcontrib>Sheitman, Brian</creatorcontrib><creatorcontrib>Lindenmayer, Jean-Pierre</creatorcontrib><creatorcontrib>McEvoy, Joseph</creatorcontrib><creatorcontrib>Cooper, Thomas B.</creatorcontrib><creatorcontrib>Chakos, Miranda</creatorcontrib><creatorcontrib>Lieberman, Jeffrey A.</creatorcontrib><title>Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia</title><title>Psychiatric services (Washington, D.C.)</title><addtitle>Psychiatr Serv</addtitle><description>OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial. The trial was divided into two periods: eight weeks during which the dosage was escalated and then fixed, and six weeks during which variable dosages were used. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the items that reflect positive symptoms of schizophrenia (delusions, suspiciousness or feelings of persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinations) and the sedation item of the Nurses Observation Scale for Inpatient Evaluation (NOSIE). RESULTS: Patients differed in their treatment response as measured by the hostility item of the PANSS. The scores of patients taking clozapine indicated significantly greater improvement than those of patients taking haloperidol or risperidone. The effect on hostility appeared to be independent of the antipsychotic effect of clozapine on other PANSS items that reflect delusional thinking, a formal thought disorder, or hallucinations and independent of sedation as measured by the NOSIE. Neither risperidone nor olanzapine showed superiority to haloperidol. CONCLUSION: Clozapine has a relative advantage over other antipsychotics as a specific antihostility agent.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Benzodiazepines</subject><subject>Biological and medical sciences</subject><subject>Clozapine - pharmacology</subject><subject>Clozapine - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Emotions - drug effects</subject><subject>Female</subject><subject>Haloperidol - pharmacology</subject><subject>Haloperidol - therapeutic use</subject><subject>Hostility</subject><subject>Humans</subject><subject>Linear Models</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pirenzepine - analogs &amp; derivatives</subject><subject>Pirenzepine - pharmacology</subject><subject>Pirenzepine - therapeutic use</subject><subject>Prospective Studies</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Psychotic Disorders - psychology</subject><subject>Risperidone - pharmacology</subject><subject>Risperidone - therapeutic use</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><subject>Statistics, Nonparametric</subject><subject>Survival Analysis</subject><issn>1075-2730</issn><issn>1557-9700</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1OGzEUha2qqNC0L8Ci8qasmODr8U-yRBGQSkhB0KpLy_XYxGjGdu3JAp4eT5OKHSvfY333XJ2D0CmQOYAUFzolP09lzmnVc-BAPqAT4Fw2S0nIxzoTyRsqW3KMPpfyRAgBCeITOgYQCybZ4gQNV85ZMxYcHV718UUnH-w53vQ6_J_vfUk2-y5OQocOr3Uf9z89jgGvYxl978dnfDnE8Ijv9OhtqJa__bjFD2brX2LaZhu8_oKOnO6L_Xp4Z-jX9dXP1bq53dz8WF3eNroVy7GxDkjruHA1R9txEMLIjgqqdVeDWwsO-JI6ZhxhrTCdNUwzIG5hOXGsE-0Mne19U45_d7aMavDF2L6msnFXlKSUEQpQQboHTY6lZOtUyn7Q-VkBUVPJaipZpaI4rVpNJdelbwf33Z_Bdm8rh1Yr8P0A6GJ077IOxpc3jpElE3wyuthz_448xV0OtZX3Tr8CQi-XJg</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>Citrome, Leslie</creator><creator>Volavka, Jan</creator><creator>Czobor, Pal</creator><creator>Sheitman, Brian</creator><creator>Lindenmayer, Jean-Pierre</creator><creator>McEvoy, Joseph</creator><creator>Cooper, Thomas B.</creator><creator>Chakos, Miranda</creator><creator>Lieberman, Jeffrey A.</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011101</creationdate><title>Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia</title><author>Citrome, Leslie ; Volavka, Jan ; Czobor, Pal ; Sheitman, Brian ; Lindenmayer, Jean-Pierre ; McEvoy, Joseph ; Cooper, Thomas B. ; Chakos, Miranda ; Lieberman, Jeffrey A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a369t-ef103f56f9703d5166c7d262aad117ee1f1592f4cf0436cdec4a410f8e50f4d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Benzodiazepines</topic><topic>Biological and medical sciences</topic><topic>Clozapine - pharmacology</topic><topic>Clozapine - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Emotions - drug effects</topic><topic>Female</topic><topic>Haloperidol - pharmacology</topic><topic>Haloperidol - therapeutic use</topic><topic>Hostility</topic><topic>Humans</topic><topic>Linear Models</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pirenzepine - analogs &amp; derivatives</topic><topic>Pirenzepine - pharmacology</topic><topic>Pirenzepine - therapeutic use</topic><topic>Prospective Studies</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Psychotic Disorders - psychology</topic><topic>Risperidone - pharmacology</topic><topic>Risperidone - therapeutic use</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><topic>Statistics, Nonparametric</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Citrome, Leslie</creatorcontrib><creatorcontrib>Volavka, Jan</creatorcontrib><creatorcontrib>Czobor, Pal</creatorcontrib><creatorcontrib>Sheitman, Brian</creatorcontrib><creatorcontrib>Lindenmayer, Jean-Pierre</creatorcontrib><creatorcontrib>McEvoy, Joseph</creatorcontrib><creatorcontrib>Cooper, Thomas B.</creatorcontrib><creatorcontrib>Chakos, Miranda</creatorcontrib><creatorcontrib>Lieberman, Jeffrey A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatric services (Washington, D.C.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Citrome, Leslie</au><au>Volavka, Jan</au><au>Czobor, Pal</au><au>Sheitman, Brian</au><au>Lindenmayer, Jean-Pierre</au><au>McEvoy, Joseph</au><au>Cooper, Thomas B.</au><au>Chakos, Miranda</au><au>Lieberman, Jeffrey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia</atitle><jtitle>Psychiatric services (Washington, D.C.)</jtitle><addtitle>Psychiatr Serv</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>52</volume><issue>11</issue><spage>1510</spage><epage>1514</epage><pages>1510-1514</pages><issn>1075-2730</issn><eissn>1557-9700</eissn><abstract>OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial. The trial was divided into two periods: eight weeks during which the dosage was escalated and then fixed, and six weeks during which variable dosages were used. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the items that reflect positive symptoms of schizophrenia (delusions, suspiciousness or feelings of persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinations) and the sedation item of the Nurses Observation Scale for Inpatient Evaluation (NOSIE). RESULTS: Patients differed in their treatment response as measured by the hostility item of the PANSS. The scores of patients taking clozapine indicated significantly greater improvement than those of patients taking haloperidol or risperidone. The effect on hostility appeared to be independent of the antipsychotic effect of clozapine on other PANSS items that reflect delusional thinking, a formal thought disorder, or hallucinations and independent of sedation as measured by the NOSIE. Neither risperidone nor olanzapine showed superiority to haloperidol. CONCLUSION: Clozapine has a relative advantage over other antipsychotics as a specific antihostility agent.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>11684748</pmid><doi>10.1176/appi.ps.52.11.1510</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1075-2730
ispartof Psychiatric services (Washington, D.C.), 2001-11, Vol.52 (11), p.1510-1514
issn 1075-2730
1557-9700
language eng
recordid cdi_proquest_miscellaneous_72240211
source MEDLINE; American Psychiatric Publishing Journals (1997-Present); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Psychiatry Legacy Collection Online Journals 1844-1996
subjects Adult
Adult and adolescent clinical studies
Antipsychotic Agents - pharmacology
Antipsychotic Agents - therapeutic use
Benzodiazepines
Biological and medical sciences
Clozapine - pharmacology
Clozapine - therapeutic use
Dose-Response Relationship, Drug
Double-Blind Method
Emotions - drug effects
Female
Haloperidol - pharmacology
Haloperidol - therapeutic use
Hostility
Humans
Linear Models
Male
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Pirenzepine - analogs & derivatives
Pirenzepine - pharmacology
Pirenzepine - therapeutic use
Prospective Studies
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychoses
Psychotic Disorders - drug therapy
Psychotic Disorders - psychology
Risperidone - pharmacology
Risperidone - therapeutic use
Schizophrenia
Schizophrenia - drug therapy
Schizophrenic Psychology
Statistics, Nonparametric
Survival Analysis
title Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T21%3A39%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Clozapine,%20Olanzapine,%20Risperidone,%20and%20Haloperidol%20on%20Hostility%20Among%20Patients%20With%20Schizophrenia&rft.jtitle=Psychiatric%20services%20(Washington,%20D.C.)&rft.au=Citrome,%20Leslie&rft.date=2001-11-01&rft.volume=52&rft.issue=11&rft.spage=1510&rft.epage=1514&rft.pages=1510-1514&rft.issn=1075-2730&rft.eissn=1557-9700&rft_id=info:doi/10.1176/appi.ps.52.11.1510&rft_dat=%3Cproquest_cross%3E72240211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72240211&rft_id=info:pmid/11684748&rfr_iscdi=true